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ricarditis,  observed  after  abdominal  surgery  or  blunt
uma.  These  causes  were  satisfactorily  ruled  out  in  our
tient,  and  only  liver  cirrhosis  was  documented  as  the
use  of  chylous  ascites,  which  is  seen  in  0.5-1%  of  cases.
e  to  the  poor  response  in  our  patient,  other  measures
ll  be  carried  out,  such  as  middle-chain  triglyceride  or
treotide  use.6,7 Another  therapeutic  option  is  the  admin-
ration  of  orlistat,  which  has  been  reported  to  reduce  the
antity  of  triglycerides  in  the  ascitic  ﬂuid  in  patients  with
rhosis.8
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tástasis múltiples en cuero cabelludo como
imera manifestación de adenocarcinoma
 páncreas
 81-year-old  woman  had  a  past  history  of  well-controlled
h  blood  pressure  and  essential  tremor  treated  with  pro-
nolol.  She  consulted  her  family  physician  after  noticing
 appearance  of  8-10  painful  lesions  on  her  scalp  over  the
t  3  weeks.  The  lesions  (ﬁg.  1)  consisted  of  ﬁrm  nodules,
hered  to  deep  layers,  between  1  and  2  cm  in  size,  and
 majority  had  an  ulcerated  surface  covered  with  small
od  clots.  She  was  referred  to  the  dermatology  service
 consultation.  Two  weeks  later,  before  said  consultation,
 presented  with  marked  mucocutaneous  jaundice,
oluria,  and  acholia,  for  which  she  came  to  the  emergency
partment  of  our  center  and  was  admitted  to  complete
r  evaluation.  A  cutaneous  biopsy  was  ordered  from  the
rmatology  service.  Blood  test  results  were  bilirubin
.2  mg/dl,  AST  111  IU/ml,  ALT  227  IU/ml,  GGT  3300  IU/ml,Please cite this article as: Tavío-Hernández E, Can˜ete-Ruiz Á,
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d  CA-19-9  436  IU/ml  (normal  limit  <  37  IU/ml).  An  abdom-
l  CT  scan  showed  a mass  located  in  the  uncinate  process
the  pancreas  that  conditioned  dilation  of  the  common
e  duct  and  duct  of  Wirsung.  Peritoneal,  pulmonary,  and
ravertebral  muscle  lesions  suggestive  of  metastasis  were
o  observed.  Due  to  these  ﬁndings,  endoscopic  ultra-
nd  ﬁne  needle  aspiration  of  the  pancreatic  mass  was
rformed.  The  scalp  biopsy  (ﬁg.  2) revealed  the  presence
cutaneous  metastases  with  morphologic  and  immuno-
tochemical  characteristics  consistent  with  a pancreatic
gin  (positive  for  cytokeratins  7  and  19  and  negative  forFigure  1  Scalp  nodule.
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Figure  2  Excisional  biopsy  of  the  scalp  lesion  showing  metastatic  adenocarcinoma:  a)  hematoxylin-eosin  stain  x4,  detail:
hematoxylin-eosin,  x40;  b)  immunohistochemical  stain  for  CK7;  c)  immunohistochemical  stain  for  CK19,  and  d)  immunohistochemical
stain for  CDX2.
cytokeratin  20).  The  sample  of  the  pancreatic  mass  con-
ﬁrmed  the  presence  of  an  adenocarcinoma  at  that  level.
The  patient  was  informed  of  her  diagnosis  and  prognosis
and  refused  any  active  treatment  for  her  disease.  Thus,
the  biliary  obstruction  was  treated  with  the  endoscopic
placement  of  a  biliary  stent  and  she  was  released  with
at-home  palliative  care.
Cutaneous  metastases  occur  in  0.6%--10.4%  of  all  patients
with  cancer,1 and  is  the  ﬁrst  disease  manifestation  in  7.8%
of  the  cases.2 When  a  lesion  suspected  of  being  cutaneous
metastasis  is  found,  in  addition  to  the  pertinent  imaging
studies,  a  biopsy  of  the  lesion  with  immunohistochemical
stain  can  provide  orientation  as  to  primary  tumor  diagno-
sis.  CK  7  and  CK  19  are  present  in  the  majority  of  pancreatic
adenocarcinomas  and  CK  20  is  negative  in  38-80%.  Stains  pos-
itive  for  CA-19-9  and  CEA  are  also  frequent.3--6 In  our  case,
immunohistochemical  stain  was  suggestive  of  a  pancreatic
origin.
Adenocarcinoma  of  the  pancreas  is  the  fourth  cause
of  cancer-related  death  and  prognosis  at  its  ﬁrst  appear-
ance  is  normally  poor,  given  that  many  cases  are  in
advanced  stages.7 The  survival  rate  of  pancreatic  adeno-
carcinoma  is  especially  devastating,  with  a  median  survival
of  approximately  5-6  months.  The  appearance  of  cuta-
neous  metastases  in  this  context  has  a  similar  impact  on
survival  with  respect  to  other  more  frequent  locations,6,8
and  it  is  customary  to  ﬁnd  other  concurrent  secondary
implants.  Therefore,  treatment  does  not  vary  with  this
presentation.
Cutaneous  metastases  are  rare  and  when  they  occur,
they  are  usually  located  in  the  periumbilical  zone,  pro-
ducing  the  lesion  known  as  the  ‘‘Sister  Mary  Joseph
Nodule’’.9,10 Outside  of  this  location,  metastases  are  uncom-
mon,  and  are  more  frequent  in  men  and  in  advanced-age
patients.6
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